Literature DB >> 9038741

Leukaemia of natural killer cell large granular lymphocyte type with HLA-DR-CD16-CD56bright+ phenotype.

J Prieto1, E Ríos, A Parrado, A Martín, J M de Blas, J M Rodríguez.   

Abstract

The case is reported of a 45 year old woman with the rare leukaemia of natural killer cell large granular lymphocyte (NK/ LGL) type. Cytometric analysis of leukaemic blasts showed that they were positive for CD2, CD38, and CD56 antigens but negative for a series of antigens including CD3, CD7, CD16, and HLA-DR. Rearrangements of the beta T cell receptor, and heavy and kappa immunoglobulin genes were not detected and neither were chromosomal abnormalities. Leukaemic blasts developed NK cytotoxicity. The patient failed to respond to aggressive chemotherapy and died three months after diagnosis. The lack of expression of HLA-DR is an extraordinary characteristic of this case, as all cases of acute NK cell leukaemias described to date expressed HLA-DR. The immunophenotype observed in the NK cell leukaemic blasts may represent the counterpart of a hypothetical normal cell precursor in an early stage of ontogenic NK cell development.

Entities:  

Mesh:

Year:  1996        PMID: 9038741      PMCID: PMC499652          DOI: 10.1136/jcp.49.12.1011

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells.

Authors:  N Imamura; Y Kusunoki; K Kawa-Ha; K Yumura; J Hara; K Oda; K Abe; H Dohy; T Inada; H Kajihara
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

3.  Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

Authors:  J S Miller; K A Alley; P McGlave
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

4.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

Authors:  G Weil-Hillman; P Fisch; A F Prieve; J A Sosman; J A Hank; P M Sondel
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

5.  CD16- CD56+ natural killer cells after bone marrow transplantation.

Authors:  R Jacobs; M Stoll; G Stratmann; R Leo; H Link; R E Schmidt
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

6.  Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma.

Authors:  J Soler; R Bordes; F Ortũno; M Montagud; J Martorell; C Pons; J Nomdedeu; J J Lopez-Lopez; J Prat; M Rutllant
Journal:  Br J Haematol       Date:  1994-03       Impact factor: 6.998

7.  Chronic natural killer cell lymphocytosis: a descriptive clinical study.

Authors:  A Tefferi; C Y Li; T E Witzig; M V Dhodapkar; S H Okuno; R L Phyliky
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

8.  Generation of LAK cells in vitro in patients with acute leukemia.

Authors:  A Parrado; J M Rodriguez-Fernandez; S Casares; P Noguerol; E Plaza; R Parody; I Espigado; J M de Blas; D Garcia-Solis
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

9.  Human natural killer cell committed thymocytes and their relation to the T cell lineage.

Authors:  M J Sánchez; H Spits; L L Lanier; J H Phillips
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  9 in total
  1 in total

1.  A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.

Authors:  Akihiko Yokohama; Anjali Mishra; Takeki Mitsui; Brian Becknell; Jessica Johns; Douglas Curphey; Bradley W Blaser; Jeffrey B Vandeusen; Hsiaoyin Mao; Jianhua Yu; Michael A Caligiuri
Journal:  Leuk Res       Date:  2009-08-05       Impact factor: 3.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.